Selective and augmented β-glucuronidase expression combined with DOX-GA3 application elicits the potent suppression of prostate cancer - PubMed (original) (raw)
. 2016 Mar;35(3):1417-24.
doi: 10.3892/or.2015.4454. Epub 2015 Nov 26.
Affiliations
- PMID: 26648021
- DOI: 10.3892/or.2015.4454
Selective and augmented β-glucuronidase expression combined with DOX-GA3 application elicits the potent suppression of prostate cancer
Longxin Wang et al. Oncol Rep. 2016 Mar.
Abstract
The present study was carried out to evaluate the specific and amplified β-glucuronidase (βG) expression in prostate cancer cells by using a prostate‑specific antigen (PSA) promoter-controlled bicistronic adenovirus and to evaluate the specific killing of prostate cancer cells after the application of the prodrug DOX‑GA3. Bicistronic adenoviral expression vectors were constructed, and the effectiveness of specific and amplified expression was evaluated using luciferase and EGFP as reporter genes. βG expression was detected in LNCaP cells after they were infected with the βG‑expressing PSA promoter-controlled bicistronic adenovirus. MTT assays were conducted to evaluate the cytoxicity on the infected cells after the application of the prodrug DOX‑GA3. Tumor growth inhibition was also evaluated in nude mice after treatment with the βG‑expressing adenovirus and DOX‑GA3. Selective and amplified expression was observed in the PSA-producing LNCaP cells, but not in the PSA‑non‑producing DU145 cells. Potent cytotoxity and a strong bystander effect were observed in the LNCaP cells after infection with the βG‑expressing adenovirus and the application of DOX‑GA3. Intravenous injection of a GAL4 regulated bicistronic adenovirus vector constructed to express βG under the control of the PSA promoter (Ad/PSAP‑GV16‑βG) and the application of DOX‑GA3 strongly inhibited tumor growth and prolonged the survival time of tumor‑bearing nude mice. Selective and amplified βG expression together with the prodrug DOX‑GA3 had an increased antitumor effect, showing great potential for prostate cancer therapy.
Similar articles
- Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein.
de Graaf M, Pinedo HM, Oosterhoff D, van der Meulen-Muileman IH, Gerritsen WR, Haisma HJ, Boven E. de Graaf M, et al. Hum Gene Ther. 2004 Mar;15(3):229-38. doi: 10.1089/104303404322886084. Hum Gene Ther. 2004. PMID: 15018732 - Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of β-glucuronidase in tumors.
Huang PT, Chen KC, Prijovich ZM, Cheng TL, Leu YL, Roffler SR. Huang PT, et al. Cancer Gene Ther. 2011 Jun;18(6):381-9. doi: 10.1038/cgt.2011.3. Epub 2011 Feb 25. Cancer Gene Ther. 2011. PMID: 21350582 - New targets for therapy in prostate cancer: modulation of stromal-epithelial interactions.
Chung LW, Hsieh CL, Law A, Sung SY, Gardner TA, Egawa M, Matsubara S, Zhau HE. Chung LW, et al. Urology. 2003 Nov;62(5 Suppl 1):44-54. doi: 10.1016/s0090-4295(03)00796-9. Urology. 2003. PMID: 14607217 Review. - Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen.
Dannull J, Belldegrun AS. Dannull J, et al. Br J Urol. 1997 Mar;79 Suppl 1:97-103. doi: 10.1111/j.1464-410x.1997.tb00809.x. Br J Urol. 1997. PMID: 9088281 Review. No abstract available.
Cited by
- Oncolytic virus: A catalyst for the treatment of gastric cancer.
Wang J, Du L, Chen X. Wang J, et al. Front Oncol. 2022 Nov 24;12:1017692. doi: 10.3389/fonc.2022.1017692. eCollection 2022. Front Oncol. 2022. PMID: 36505792 Free PMC article. Review. - Gene-Directed Enzyme Prodrug Therapy by Dendrimer-Like Mesoporous Silica Nanoparticles against Tumor Cells.
Candela-Noguera V, Vivo-Llorca G, Díaz de Greñu B, Alfonso M, Aznar E, Orzáez M, Marcos MD, Sancenón F, Martínez-Máñez R. Candela-Noguera V, et al. Nanomaterials (Basel). 2021 May 14;11(5):1298. doi: 10.3390/nano11051298. Nanomaterials (Basel). 2021. PMID: 34069171 Free PMC article. - Targeting strategies of adenovirus‑mediated gene therapy and virotherapy for prostate cancer (Review).
Cai Z, Lv H, Cao W, Zhou C, Liu Q, Li H, Zhou F. Cai Z, et al. Mol Med Rep. 2017 Nov;16(5):6443-6458. doi: 10.3892/mmr.2017.7487. Epub 2017 Sep 13. Mol Med Rep. 2017. PMID: 28901490 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous